FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379332800> ?p ?o ?g. }

• W4379332800 endingPage "4573" @default.
• W4379332800 startingPage "4573" @default.
• W4379332800 abstract "4573 Background: EV is used for treatment-refractory aUC with activity also noted in a frontline trial. Independent biomarkers associated with EV treatment outcomes are lacking. Methods: UNITE is a multi-site retrospective study of pts treated with EV and other agents. In this analysis we included pts treated with EV monotherapy and available next generation sequencing (NGS) data. Assessed biomarkers included genomic alterations (alts) in ≥5% of pts, tumor mutation burden (TMB) and PD-L1 expression. Pts were evaluable for observed response rate (ORR) if they had scans after ≥1 EV cycle. Biomarkers were evaluated individually in univariate analyses (UVA) and in separate multivariate analyses (MVA) which accounted for clinical variables. Progression-free survival (PFS) and overall survival (OS) from EV start were assessed using Kaplan Meier method and cox proportional hazard (cph) modeling. ORR was assessed using logistic regression. Results: Among 303 pts with NGS treated with EV monotherapy at 16 US sites, 207 had TMB and 146 had PD-L1 data. Median age was 70; 218 (72%) men, 262 (87%) White, 196 (66%) with pure urothelial histology, 212 (71%) with lower tract primary tumor, 204 (67%) had ≥2 prior therapies. ORR was 53% (140/264); mPFS was 6.0 mos, mOS was 13.1 mos. In UVA, longer OS was associated with higher Hgb, albumin and GFR (>30cc/min), lower neutrophil to lymphocyte ratio, older age, and absence of liver mets. MVA included these variables along with histology as covariates. In multivariate cph models, better outcomes were associated with alts in ERBB2, KDM6A and PIK3CA, while inferior outcomes with low TMB (<10 Mut/Mb) and high PD-L1 (CPS ≥ 10). Conclusions: MVA of this large, multi-site, retrospective cohort of aUC pts, identified several putative biomarkers independently associated with EV treatment outcomes. Longer OS was associated with ERBB2 and KDM6A alts, low PD-L1 and high TMB. Limitations include lack of central scan review, pt selection and confounding biases. These findings require external validation, while their underlying mechanisms merit translational study. [Table: see text]" @default.
• W4379332800 created "2023-06-05" @default.
• W4379332800 creator A5003873827 @default.
• W4379332800 creator A5008861348 @default.
• W4379332800 creator A5010746028 @default.
• W4379332800 creator A5017229890 @default.
• W4379332800 creator A5020125488 @default.
• W4379332800 creator A5023616396 @default.
• W4379332800 creator A5026717218 @default.
• W4379332800 creator A5031234862 @default.
• W4379332800 creator A5044876102 @default.
• W4379332800 creator A5049071296 @default.
• W4379332800 creator A5049546835 @default.
• W4379332800 creator A5056451633 @default.
• W4379332800 creator A5057146540 @default.
• W4379332800 creator A5066716873 @default.
• W4379332800 creator A5070016877 @default.
• W4379332800 creator A5072435293 @default.
• W4379332800 creator A5074756323 @default.
• W4379332800 creator A5083920381 @default.
• W4379332800 creator A5085652006 @default.
• W4379332800 creator A5090727184 @default.
• W4379332800 date "2023-06-01" @default.
• W4379332800 modified "2023-10-06" @default.
• W4379332800 title "Independent biomarkers predictive of outcomes with enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study." @default.
• W4379332800 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.4573" @default.
• W4379332800 hasPublicationYear "2023" @default.
• W4379332800 type Work @default.
• W4379332800 citedByCount "0" @default.
• W4379332800 crossrefType "journal-article" @default.
• W4379332800 hasAuthorship W4379332800A5003873827 @default.
• W4379332800 hasAuthorship W4379332800A5008861348 @default.
• W4379332800 hasAuthorship W4379332800A5010746028 @default.
• W4379332800 hasAuthorship W4379332800A5017229890 @default.
• W4379332800 hasAuthorship W4379332800A5020125488 @default.
• W4379332800 hasAuthorship W4379332800A5023616396 @default.
• W4379332800 hasAuthorship W4379332800A5026717218 @default.
• W4379332800 hasAuthorship W4379332800A5031234862 @default.
• W4379332800 hasAuthorship W4379332800A5044876102 @default.
• W4379332800 hasAuthorship W4379332800A5049071296 @default.
• W4379332800 hasAuthorship W4379332800A5049546835 @default.
• W4379332800 hasAuthorship W4379332800A5056451633 @default.
• W4379332800 hasAuthorship W4379332800A5057146540 @default.
• W4379332800 hasAuthorship W4379332800A5066716873 @default.
• W4379332800 hasAuthorship W4379332800A5070016877 @default.
• W4379332800 hasAuthorship W4379332800A5072435293 @default.
• W4379332800 hasAuthorship W4379332800A5074756323 @default.
• W4379332800 hasAuthorship W4379332800A5083920381 @default.
• W4379332800 hasAuthorship W4379332800A5085652006 @default.
• W4379332800 hasAuthorship W4379332800A5090727184 @default.
• W4379332800 hasConcept C126322002 @default.
• W4379332800 hasConcept C143998085 @default.
• W4379332800 hasConcept C144301174 @default.
• W4379332800 hasConcept C151956035 @default.
• W4379332800 hasConcept C207103383 @default.
• W4379332800 hasConcept C38180746 @default.
• W4379332800 hasConcept C44249647 @default.
• W4379332800 hasConcept C50382708 @default.
• W4379332800 hasConcept C71924100 @default.
• W4379332800 hasConcept C90924648 @default.
• W4379332800 hasConceptScore W4379332800C126322002 @default.
• W4379332800 hasConceptScore W4379332800C143998085 @default.
• W4379332800 hasConceptScore W4379332800C144301174 @default.
• W4379332800 hasConceptScore W4379332800C151956035 @default.
• W4379332800 hasConceptScore W4379332800C207103383 @default.
• W4379332800 hasConceptScore W4379332800C38180746 @default.
• W4379332800 hasConceptScore W4379332800C44249647 @default.
• W4379332800 hasConceptScore W4379332800C50382708 @default.
• W4379332800 hasConceptScore W4379332800C71924100 @default.
• W4379332800 hasConceptScore W4379332800C90924648 @default.
• W4379332800 hasIssue "16_suppl" @default.
• W4379332800 hasLocation W43793328001 @default.
• W4379332800 hasOpenAccess W4379332800 @default.
• W4379332800 hasPrimaryLocation W43793328001 @default.
• W4379332800 hasRelatedWork W1998259048 @default.
• W4379332800 hasRelatedWork W2149196106 @default.
• W4379332800 hasRelatedWork W2361700749 @default.
• W4379332800 hasRelatedWork W2751913398 @default.
• W4379332800 hasRelatedWork W2771629182 @default.
• W4379332800 hasRelatedWork W2789279481 @default.
• W4379332800 hasRelatedWork W2889343797 @default.
• W4379332800 hasRelatedWork W3093242228 @default.
• W4379332800 hasRelatedWork W4283321516 @default.
• W4379332800 hasRelatedWork W4361918880 @default.
• W4379332800 hasVolume "41" @default.
• W4379332800 isParatext "false" @default.
• W4379332800 isRetracted "false" @default.
• W4379332800 workType "article" @default.